Share: Facebook Twitter LinkedIn
Activity Provided By:

The Rx Consultant

Direct-Acting Oral Anticoagulants

Access Activity

Overview / Abstract:

This issue will review the evidence supporting DOACs and their place in therapy for: 1) atrial fibrillation (AF); 2) the acute treatment and long-term secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE); and 3) DVT and PE prevention after major orthopedic surgery and in medically ill patients. The differences among DOACs will be highlighted (eg, side effect profiles, dosing considerations and drug interactions), and DOACs will be compared with warfarin for conditions where both are indicated. Bleeding management and the use of reversal agents will also be addressed.

For more than 50 years, vitamin K antagonists (VKAs) such as warfarin were the only oral anticoagulant options for patients with blood clotting disorders. In 2010, dabigatran (Pradaxa®) - a direct thrombin inhibitor - became the first approved agent from the next generation of oral anticoagulants. Over the next 7 years, 4 factor Xa inhibitor oral anticoagulants were FDA approved. These include rivaroxaban (Xarelto®), apixaban (Eliquis®), edoxaban (Savaysa™), and most recently, betrixaban (Bevyxxa®). Early on, this generation of oral anticoagulants was referred to as NOACs (Novel Oral AntiCoagulants). However, the Institute For Safe Medication Practices (ISMP) issued a safety alert because “NoAC” was interpreted as “no anticoagulation” in a patient at high risk of stroke. The ISMP designated “NoAC” a potentially dangerous abbreviation and discourages its use. Today, the acronym DOAC, for Direct-acting Oral AntiCoagulant, is the abbreviation most widely used to distinguish these medications from warfarin.


Nov 23, 2021


Nursing CNE, Pharmacy CPE





Credits / Hours




Presenters / Authors / Faculty

Kristen Tasca, PharmD, BCPS is a Clinical Pharmacist at Cedars- Sinai Medical Center in Los Angeles, CA. She assists with the hospital anticoagulation program. Dr. Tasca has also served as a Clinical Pharmacy Specialist in the Cardiology department at University of North Carolina Hospitals, Chapel Hill, NC.

Activity Specialities / Related Topics

Cardiology / Cardiovascular

Keywords / Search Terms

Continuing Education Network Inc. Direct-Acting Oral Anticoagulants, vitamin K antagonists, Pradaxa®, Xarelto®, Eliquis®, SavaysaTM, Eliquis®), Eliquis®), Novel Oral AntiCoagulants, Bleeding management, reversal agents, Warfarin

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map